The Italian Journal of Neurological Sciences

, Volume 13, Issue 8, pp 643–647 | Cite as

Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione

  • Bogliun G. 
  • Marzorati L. 
  • Cavaletti G. 
  • Frattola L. 
Original Articles

Abstract

The use of high doses of cisplatin (DDP) in the treatment of different solid tumors is often prevented by the onset of a disabling sensory neuropathy. In an attempt to minimize DDP-induced neurotoxicity different schedules of DDP administration have been tested. Moreover, during the past few years some putative neuroprotective drugs have been reported as reducing DDP neurotoxicity. In this prospective, randomized study we evaluated in a series of 33 patients affected by relapsing ovarian cancer the effect on the sensory pathway of a non-conventional schedule of DDP administration as monochemiotherapy or in combination with one of the neuroprotective drugs (i.e. glutathione). The results of the neurophysiologic examinations performed before and immediately after chemotherapy suggest that these schedules besides being safe and effective in the treatment of the ovarian cancer, have an extremely low peripheral neurotoxicity.

Key Words

Cisplatin glutathione sensory neuropathy neurophysiology 

Sommario

L'uso di alte dosi di cisplatino (DDP) nel trattamento di diversi tipi di tumore solido è spesso impedito dalla insorgenza di una grave neuropatia periferica. Nel tentativo di ridurre l'incidenza di questa complicanza sono state sperimentate diverse, modalità di somministrazione del DDP. Inoltre alcuni autori hanno proposto l'utilizzo di sostanze “neuroprotettive”, tra le quali il glutatione ridotto (GSH), da associare al DDP. In questo studio prospettico randomizzato abbamo studiato un gruppo di 33 pazienti affette da recidiva di tumore ovarico. Tutte le pazienti sono state sottoposte a valutazione neurofisiologica mediante potenziali evocati con l'obiettivo di valutare gli effetti della somministrazione di DDP (alla dose di 50 mg/m2 settimanale per 9 cicli) come monochemioterapia o associato a GSH sulla via sensitiva. Il confronto dei risultati ottenuti prima e dopo chemioterapia suggeriscono che queste modalità di somministrazione sono sicure, ben tollerate ed efficaci da un punto di vista oncologico. Inoltre la loro neurotossicità si è dimostrata estremamente ridotta.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Arrich B.A., Nathan C.F.:Glutathione metabolism as a determinant of therapeutic efficacy. Cancer Res. 44:4224–4232, 1984.Google Scholar
  2. [2]
    Boogerd W., Ten Bokkel Huinink W.W., Dalesio O. et al.:Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J. Neuro-Oncol. 9:255–263, 1990.CrossRefGoogle Scholar
  3. [3]
    Cavaletti G., Bogliun G., Marzorati L. et al.:The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J. Neurol. 238:371–374, 1991.CrossRefPubMedGoogle Scholar
  4. [4]
    Cavaletti G., Marzorati L., Boglium G. et al.:Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69:203–207, 1991.Google Scholar
  5. [5]
    Cavaletti G., Petruccioli, M.G., Tredici G. et al.:Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int. J. Tiss. Reac. 18:151–157, 1991.Google Scholar
  6. [6]
    Daugaard G.K., Petrera J., Trojaborg W.:Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol. Scand. 76:86–93, 1987.PubMedGoogle Scholar
  7. [7]
    Dewar J., Lunt H., Abernethy D.A. et al.:Cisplatin neuropathy with Lhermitte's sign. J. Neurol. Neurosurg. Psychiat., 49:96–99, 1986.PubMedGoogle Scholar
  8. [8]
    Di Re F., Bohm S., Oriana S. et al.:Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother. Pharmacol. 25:355–360, 1990.CrossRefPubMedGoogle Scholar
  9. [9]
    Dyck P.J., Sherman W.R., Hallker L.M. et al.:Human diabetic endoneural sorbitol, fructose and myo-inositol related to sural, nerve morphometry. Ann. Neurol. 8:590–596, 1980.CrossRefPubMedGoogle Scholar
  10. [10]
    Herchbergs A., Brok-Simoni F., Holtzman F. et al.:Erythrocyte glutathione and tumor response to chemotherapy. Lancet 339:1074–1076, 1992.Google Scholar
  11. [11]
    van der Hoop R.G., Vecht C.J., van den Burg M.E.L. et al.:Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N. Engl. J. Med. 322:89–94, 1990.PubMedGoogle Scholar
  12. [12]
    Mollman J.E., Glover D.J., Hogan W.M., Furman R.E.:Cisplatin, neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 61:2192–2195, 1988.PubMedGoogle Scholar
  13. [13]
    Mollman J.E. Cisplatin neurotoxicity. N. Engl. J. Med. 322:126–127, 1990.PubMedGoogle Scholar
  14. [14]
    Ongerboer de Visser B.W., Tiesens G.:Polyneuropathy induced by cisplatin. Prog. Exp. Tumor Res. 29, 190: 196, 1985.Google Scholar
  15. [15]
    Roelofs R.I., Hrushesky W., Rogin J., Rosenberg L.:Peripheral sensory neuropathy and cisplatin chemotherapy. Neurol. 34:934–938, 1984.Google Scholar
  16. [16]
    Rosenberg B.:Fundamental studies with cisplatin. Cancer 55:2303–2316, 1985.PubMedGoogle Scholar
  17. [17]
    Tomiwa, K., Nolan C., Cavanagh J.B.:The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphomelight and electron microscopy and by morphometry. Acta Neuropathol. (Berl.), 69:295–308, 1986.CrossRefGoogle Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1992

Authors and Affiliations

  • Bogliun G. 
    • 1
  • Marzorati L. 
    • 1
  • Cavaletti G. 
    • 1
  • Frattola L. 
    • 1
  1. 1.Istituto di Ricerche Biomediche S. GerardoClinica Neurologica, Università di MilanoMonza

Personalised recommendations